Please login to the form below

Not currently logged in
Email:
Password:

Ron Menezes joins Almirall’s Aqua Pharmaceuticals

He joins the US dermatology group as its president and general manager

Amirall's US dermatology company Aqua Pharmaceuticals has appointed Ron Menezes as its new president and general manager.

Menezes joins the group from Depomed Pharmaceuticals, where he served as vice president of sales and sales operations, pain and CNS.

Prior to his role at Depomed, Menezes was at Allergan in senior roles including vice president sales and marketing, medical dermatology and he has also held positions at Abbott, Astellas and Pfizer.

Eduardo Sanchiz, chief executive officer at Almirall, said: “We are very pleased to announce the appointment of Ron Menezes as the new president and GM of Aqua Pharmaceuticals.

“Ron’s incorporation and he experience he brings in dermatology represent a clear and undeniable opportunity to further strengthen this organisation.”

Menezes will replace Ted White, who has been president and general manager of Aqua Pharmaceuticals since January 2016.

Sanchiz added: “Almirall continues to consider Aqua as a very important platform in the US market to support existing and new products.”

Aqua Pharmaceuticals was acquired by the Spanish group back in 2013 - a deal that was worth around $400m - to access the US dermatology market.

23rd August 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics